Photo from Paolo Tarantino / Twitter
Aug 15, 2023, 09:15
Paolo Tarantino: Delivering chemo via HER2- and Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC)
Paolo Tarantino, MD, Clinical Research Fellow at Dana-Farber Cancer Institute, stated on Twitter:
“Delivering chemo via HER2- & Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC). Beyond these two targets lays a vast land of opportunity, encompassing additional targets & novel ADC structures. Our latest review, led by Ilana Schlam, just out on CROH.”
For the article click here
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19